Galantamine is a reversible acetylcholinesterase inhibitor used primarily in the treatment of mild to moderate alzheimer's disease. It functions by increasing the availability of acetylcholine at synaptic junctions in the central nervous system. By inhibiting the enzyme that degrades acetylcholine, it enhances cholinergic neurotransmission. This augmentation of cholinergic activity compensates for the loss of neurons that normally release the neurotransmitter. The drug also acts as a positive allosteric modulator of nicotinic receptors involved in memory and attention. The combined inhibition of acetylcholinesterase and modulation of nicotinic receptors contributes to improvements in cognitive function. Pharmacodynamically, the enhanced cholinergic signaling leads to better encoding and recall of information. Overall, the mechanism of action of Galantamine targets the underlying neurochemical deficits associated with alzheimer's disease.

Galantamine is a naturally derived alkaloid used as a medication for cognitive impairment. It acts as an acetylcholinesterase inhibitor that increases levels of the neurotransmitter acetylcholine in the brain. By preventing the breakdown of acetylcholine it enhances cholinergic signaling involved in memory and attention. This mechanism supports its therapeutic role in improving symptoms of mild to moderate alzheimer disease. The drug crosses the blood-brain barrier and binds to the catalytic site of the enzyme to achieve inhibition. Overall Galantamine provides symptomatic relief through modulation of cholinergic pathways.

The most common side effects often involve mild reactions that occur soon after exposure. Headache and fatigue are frequently reported among users of many medications. Nausea and gastrointestinal discomfort are also commonly noted in clinical observations. Some individuals experience temporary skin sensations such as tingling or flushing. Dizziness and mild drowsiness are additional symptoms that appear regularly. These effects tend to be short lived and often diminish as the body adjusts. Monitoring personal responses helps distinguish typical occurrences from more unusual reactions.

Many people experience mild fatigue after vaccination. Headaches are also reported in a noticeable number of cases. Some individuals notice mild muscle aches that resolve within a day or two. Nausea can occur, though it is usually short lived. Swelling or redness at the injection site is a common local reaction. Fever and chills may appear, particularly after booster doses. These effects typically diminish as the body adapts to the stimulus.